Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.
Share or print this source review
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.
Clinical context remains essential
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
Check source scope before reading a dose
KINERET - official renal dosing and indication distinction
Product / population
Subcutaneous anakinra: RA versus NOMID/DIRA doses remain distinct.
Renal method
CrCl <30 mL/min, including ESRD.
Source revision
October 2025
Retrieved
2026-09-07
Local review status
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Documented differences and cautions on this drug
All record notes are retained here, including notes about sources not selected in this review.
Renal interval change does not substitute the adult RA dose
The official label considers alternate-day administration of the prescribed dose below CrCl 30. The adult RA 100 mg dose is not the weight-based NOMID/DIRA dose.
What to reconcile: Retain indication and population when changing the interval. The separate official retrieval does not repair the failed RX page attempt.
DailyMed / Swedish Orphan Biovitrum · Subcutaneous anakinra: RA versus NOMID/DIRA doses remain distinct.
Renal method: CrCl <30 mL/min, including ESRD. Source date: October 2025 Retrieved: 2026-09-07
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Renal dosing, restrictions and evidence limits
For severe impairment or ESRD (CrCl <30), consider the prescribed dose every other day. For adult RA this is 100 mg every other day. NOMID/DIRA use the individually prescribed weight-based dose, not an automatic adult 100 mg substitution. Hemodialysis/CAPD removed <2.5% in the PK study; no inferred post-dialysis supplement is added. Assess neutrophils before treatment, monthly for three months, then quarterly through one year. Full infection and immunization precautions remain necessary.
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
GlobalRPh v6.6 | RDM66-DIRECT-PHP-20260911 | Local library date 2026-09-11. Selected-card identity does not imply clinical verification.